Year: 2026

DALLAS, June 09, 2026 (GLOBE NEWSWIRE) — Ridgepost Capital, Inc (NYSE: RPC), today announced that Brian McKenna will join the firm as Vice President, Investor Relations, effective June 15, 2026. Brian brings extensive experience across equity research and the alternative asset management industry. Most recently, he served as a senior research analyst and managing director covering the alternative asset managers and business development companies (BDCs), a part of the market he’s covered for over a decade. In his new role, Brian will be responsible for leading Ridgepost Capital’s investor relations strategy, strengthening relationships with institutional investors, and enhancing communication across the firm’s global investor base. He will also oversee the firm’s press and media engagement, including the development of press releases...

FREUDENSTADT, Germany, June 09, 2026 (GLOBE NEWSWIRE) — SCHMID Group N.V. (NASDAQ: SHMD) (“SCHMID”), a global leader in advanced manufacturing solutions for the electronics and semiconductor industries, today announced that it has signed a preliminary manufacturing project letter of intent and investment framework agreement with local authorities in Banfu Industrial Zone, Zhongshan, Guangdong Province, China, regarding the establishment of a new manufacturing campus. The planned facility will consolidate SCHMID’s existing manufacturing operations currently located at two separate leased facilities into a single company-owned production campus. As a result, SCHMID expects the new facility to provide nearly double the effective manufacturing capacity of its current China operations, through the extension of operational space,...

Company Continues Delivering on Aggressive 2026 Expansion Strategy as Production Scale Reaches New Heights ANN ARBOR, Mich., June 09, 2026 (GLOBE NEWSWIRE) — Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“the Company”, “Kraig Labs”, or “Kraig’s”), a world leader in spider silk technology*, today announced the successful completion of its latest production cycle (harvest from May 15 to June 4). This is the largest in the Company’s history, producing nearly 2.5 metric tons of recombinant spider silk cocoons. The milestone represents the Company’s most significant single-cycle output to date and delivers another powerful proof point in Kraig Labs’ aggressive 2026 expansion strategy. With each successive production cycle, Kraig Labs has demonstrated a systematic ability...

– Successful End-of-Phase 2 meeting with FDA agreeing on key elements of the proposed Phase 3 design, including study population, dosing regimen, and treatment duration – – FDA agrees on UMSARS Part I as primary endpoint after ATH434 demonstrated 48% slowing of disease progression versus placebo in Phase 2 study – – FDA agrees with 50mg dose level which achieved clinically and statistically significant efficacy in Phase 2 study – – Pivotal Phase 3 trial activities on track to initiate by year-end 2026 – MELBOURNE, Australia and SAN FRANCISCO, June 09, 2026 (GLOBE NEWSWIRE) — Alterity Therapeutics (ASX: ATH, trading under the ASX code ATHDA until 12 June; NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced the successful...

LIBERTY clinical trial will evaluate the comparative safety and tolerability of VYD2311 versus mRNA COVID-19 vaccine, as well as explore the safety and immunology of co-administered VYD2311 and mRNA COVID-19 vaccine Depending on study recruitment rate, Invivyd expects to report topline data from LIBERTY in Q3 2026, to accompany anticipated data from the pivotal DECLARATION clinical trial Prior exploration of monoclonal antibody (mAb) interaction with vaccine published here suggests a minimal clinical consequence to a similar interaction today, but could provide data to aid in potential product labelling language, if approved. This earlier work demonstrated an expected, modest reduction in vaccine-induced neutralizing antibody titers from co-administration of mAb and vaccine, in seronegative populations, with T Cell and other vaccine-induced...

TORONTO, June 09, 2026 (GLOBE NEWSWIRE) — Fury Gold Mines Limited (TSX and NYSE American: FURY) (“Fury” or the “Company”) is pleased to announce it has engaged a team of technical consultants to lead the next phase of development for its Eau Claire Gold Project (“Eau Claire” the “Project), located in the Eeyou-Istchee/James Bay region of northern Quebec. This engagement marks the start of the Company’s pre-feasibility study (“PFS”) work to be completed in accordance with National Instrument 43-101 standards. The PFS is the continuation of the preliminary economic assessment study issued in 2025 (see news release dated September 2, 2025). The Company has retained the services of SGS Geological Services (“SGS”), recognized for its global expertise in geological modeling and resource estimation and BBA Consultants (“BBA”), a top Canadian...

COPENHAGEN, Denmark, June 9, 2026 – Bavarian Nordic A/S (OMX: BAVA) today announced the award of a government contract valued over DKK 700 million to supply its MVA-BN® smallpox/mpox vaccine to an undisclosed country in 2026 and 2027. Paul Chaplin, President & CEO of Bavarian Nordic, said: “We are pleased to expand our commitment to supporting governments in their efforts to protect populations against mpox and smallpox. MVA-BN remains a critical tool for both outbreak response and long-term stockpiling. Ensuring reliable access to medical countermeasures requires sustained investment in preparedness, strategic stockpiles and manufacturing capabilities that can be mobilized when needed. Through continued regulatory expansion and manufacturing scale-up, Bavarian Nordic is helping to strengthen public health resilience and readiness...